News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–23
Matches
23
Sources here
9
Companies here
1
Search results Stored financial headlines

Active search

23 matching headlines

Ticker or company: GLMDMain company stories
Clear
Latest

Stock Titan Market update

Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026

Galmed Pharmaceuticals (GLMD) has announced a 1-for-8 reverse share split, consolidating its ordinary shares, with post-split trading expected to begin on August 19, 2026, on the Nasdaq Capital Market. This action will reduce the number of outstanding shares from 8,332,518 to approximately 1,041,565 and adjust the par value and authorized share capital accordingly. The split is intended to …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
TradingKey Earnings Main company 🇺🇸 United States

Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Galmed Pharmaceuticals Ltd (GLMD) has an earnings forecast score of 6.00, placing it 329th out of 387 in the Biotechnology & Medical Research industry. Based on one analyst, the company currently holds a "Hold" rating. The previous quarter's EPS was USD -0.80 against a …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Analyst action Main company 🇺🇸 United States

Galmed Pharmaceuticals Ltd (GLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Galmed Pharmaceuticals Ltd (GLMD), focusing on its volatility, financial risk, and investment risk. It highlights the company's current risk assessment score, its beta value relative to the S&P 500 index, and various metrics related to return, drawdown, …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Stock Titan Earnings Main company 🇺🇸 United States

Galmed Pharmaceuticals (NASDAQ: GLMD) terminates Yissum license agreement

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has terminated its 2021 License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., effective July 31, 2026. This strategic decision aims to consolidate operations, reduce costs, and reallocate resources towards the commercialization of Colospan …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Galmed Pharmaceuticals (GLMD) reports higher CNS exposure with new Aramchol ODF in Parkinson’s

Galmed Pharmaceuticals announced preclinical progress on a new orally dispersible film (ODF) formulation of Aramchol for Parkinson's disease, showing significantly higher systemic bioavailability and CNS exposure compared to conventional oral administration. This ODF formulation is designed to improve administration and adherence, especially for Parkinson's …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

GLMD|Galmed Pharmaceuticals Ltd|Price:0.543|Chg%:+0.009

This article provides a comprehensive stock analysis of Galmed Pharmaceuticals Ltd (GLMD), highlighting its stable fundamentals, high growth potential, and fair valuation compared to its industry peers. The company's main focus is on developing Aramchol for treating non-alcoholic steatohepatitis (NASH). Despite average recent stock …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Market update Main company 🇺🇸 United States

Galmed advances Parkinson’s drug formulation with higher CNS exposure

Galmed Pharmaceuticals Ltd. announced significant progress in a new orally dispersible film formulation of Aramchol for Parkinson’s disease. This new formulation significantly increases systemic bioavailability and central nervous system exposure compared to conventional oral methods, addressing issues like dysphagia common in Parkinson's patients. Galmed …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
PR Newswire Market update Main company 🇺🇸 United States

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

Galmed Pharmaceuticals Ltd. announced significant progress in developing a new orally dispersible film (ODF) formulation for its SCD1 inhibitor, Aramchol, targeting Parkinson's disease. This brain-penetrating formulation demonstrates 150% higher systemic bioavailability and 300% increased CNS exposure compared to conventional oral administration, addressing dysphagia common …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Galmed Pharmaceuticals Ltd (GLMD), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in shares held and proportion.

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Galmed Pharmaceuticals Ltd

The article provides a financial snapshot of Galmed Pharmaceuticals Ltd (GLMD), detailing its current stock price, market capitalization, and a note that its revenue breakdown by business segment and region has not yet been disclosed by the company. It highlights the stock's recent performance …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Galmed Pharmaceuticals Ltd (GLMD) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Galmed Pharmaceuticals Ltd (GLMD) dividends and stock splits. It notes that no dividends have been distributed in the past five years and lists several merger-related stock splits with August 28, 2024, and May 12, 2023, as key dates. …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Galmed Pharmaceuticals Ltd. Revenue Breakdown – NASDAQ:GLMD

This article provides an overview of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) financials, specifically focusing on revenue breakdown. It highlights that detailed financial data, including segments and regional performance, would be available from sources like ICE Data Services and FactSet, accessed via TradingView. The article …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

GLMD|Galmed Pharmaceuticals Ltd|Price:0.513|Chg%:-0.040

This article provides a detailed overview of Galmed Pharmaceuticals Ltd (GLMD), covering its current market trends, financial performance, and analyst ratings. It highlights the company's focus on developing therapeutics for liver diseases, particularly its flagship product Aramchol for NASH. Despite recent weak stock market …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Galmed Pharmaceuticals Ltd (GLMD), giving it a current financial score of 6.02 and ranking it 298 out of 386 in the Biotechnology & Medical Research industry. The report indicates the company's financial status is weak with …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Galmed Pharmaceuticals Ltd (GLMD) Institutional Confidence

This article from TradingKey provides an "Institutional Confidence" score for Galmed Pharmaceuticals Ltd (GLMD), which currently stands at 3.00 with no change. It details the institutional shareholding, listing top holders like Two Sigma Investments and Citadel Advisors, along with their respective share counts and …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Globe and Mail Market update Main company 🇺🇸 United States

Galmed Pharmaceuticals Sets August 26, 2026 Annual Meeting to Approve Governance and Structural Changes

Galmed Pharmaceuticals (GLMD) has announced its Annual General Meeting for August 26, 2026, in Ramat Gan, Israel. Key agenda items include re-electing directors, amending articles of association to eliminate par value and change the company name, approving a new compensation policy, and reappointing auditors. …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

GLMD Q2'26 Earnings: EPS estimate is (0.39) USD

Galmed Pharmaceuticals Ltd. (GLMD) is anticipated to release its Q2'26 earnings on July 30th, with an estimated Earnings Per Share (EPS) of (0.39) USD. The article provides a table of historical and estimated revenue and EPS figures, highlighting past EPS surprises.

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Galmed Pharmaceuticals (GLMD) sets 2026 AGM on name change and pay

Galmed Pharmaceuticals will hold its Annual General Meeting on August 26, 2026, where shareholders will vote on critical proposals including re-electing directors, changing the company's name to Eocene Ltd., and approving an updated executive and director compensation policy that features increased bonuses and director …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Indian Pharma Post Analyst action Main company 🇺🇸 United States

Galmed unveils heart-targeted Aramchol in cardiac fibrosis push

Galmed Pharmaceuticals has developed a new lipid nanoparticle (LNP) formulation of its drug Aramchol, designed to selectively target heart tissue for treating cardiac fibrosis. This innovation, in collaboration with Barcode Nanotech, aims to overcome delivery challenges by redirecting Aramchol away from the liver and …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs

Galmed Pharmaceuticals (NASDAQ: GLMD) announced a breakthrough in developing a novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, that specifically targets heart tissue. This new formulation aims to redirect Aramchol's biodistribution away from the liver and towards the heart muscle, potentially offering …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
InvestorsHub Market update Main company 🇺🇸 United States

Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)

Galmed (NASDAQ:GLMD) has developed a new cardiac-targeted formulation of Aramchol, its SCD1 inhibitor, using lipid nanoparticles in collaboration with Barcode Nanotech. This innovation aims to redirect the drug from the liver to the heart, expanding its potential application beyond liver and gastrointestinal programs to …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Australia Deals and strategy Main company 🇺🇸 United States

Galmed develops heart-targeted formulation of Aramchol drug By Investing.com

Galmed Pharmaceuticals Ltd. has developed a new lipid nanoparticle formulation of its drug Aramchol that specifically targets heart tissue, in collaboration with Barcode Nanotech. This new formulation aims to address cardiac fibrosis, a major contributor to heart failure, by redirecting Aramchol's known anti-fibrotic effects …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
PR Newswire Market update Main company 🇺🇸 United States

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

Galmed Pharmaceuticals Ltd. has announced the development of a new lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, designed for targeted delivery to the heart. This breakthrough, developed in collaboration with Barcode Nanotech, aims to redirect Aramchol's established anti-fibrotic effects from the liver …

GLMD main company
Sharemaestro market context Price below Trend Line 52 weeks -64.9% · Next-week setup negative 40.7% GLMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context